The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thank's JEZ2
What channel is this on is it local or mainstream. National.???
i here Sunday?
Allthewinners
tweeted
Is this T.B Winding us up ??
they will buy up all the shares at this price then drive the price down again.IMO
Andy 216
just had my second , nurse you have one every year from now on with whatever is doing the rounds.
KB007
Historically the market used to peak in July , drop, then Peak in August again. selling in May is way to early. many of the crashes have been in October Fridays and Mondays in my experience.
this is certainly a manufactured takeover, brokers have been forecasting between £.85 and £1.20. they've issued the shares at £.45 DRIVEN THE PRICE Down to around 40 pence then averaged the price and given us a 50% sucker punch. no where near the lowest broker ratings. this is what take over companies do. i am afraid that's what is happening here . happened to me at Welsh Water. with this share i bought in at a pound halved my holding at £2.5 now , i'm playing free of risk. but still believe it's worth hanging in there for an increased and fairer offer.
Garet3627
yes Gareth this is a long haul out , my Lipids consultant is in the high risk group, still not doing face to face appointments , so i shall give him a 10 pack on me because he hasn't heard of them yet.
India is sadly going to be a huge problem.
IKj1
i had share's once in welsh water , at it's peak they were £10. some company wanted to take them over, and they bought big and sold even bigger ,they drove the price down to about £2. then it rose to £4 when i finally had to sell as they had 90 pc of the company. so beware of BIG buys. not alway's good .???? in my experience
nearly 7% spread . how you supposed to make money.??
loon ,
did just that.
ummm Felicity Kate Sartain, British nationality . beg your pardon fellow idiots.
Jez She may have a french name , but i wager she is of Indian origin.
About
Felicity Sartain
Felicity has over 10 years of managerial, commercial and research experience in the life sciences, med tech and clean tech sectors. She is the founder of Profiscio and oversees all projects. Prior to this Felicity was the Programme Director at Bio Nano Consulting, where she managed and delivered multimillion pound nanotechnology projects, developed market and business opportunities and secured global contracts. Working at GlaxoSmithKline and at Smart Holograms, where she was a co-inventor of the original technologies, provided her with hands-on experience of commercial research and development. Felicity holds an MChem in Chemistry with Life Sciences and Pharmaceuticals from the University of York, and a PhD from the University of Cambridge. She is an advisor on the European HealthTech Translation Advisory Board, a member of the Royal Society of Chemistry and a STEMNet Ambassador
Felicity is supported by trusted associates who have complimentary skills and experience. Individuals are drafted in on an as needed basis adding value to our offering.
earl.
good spot . she is the founder of the company and has secured multi million pound deals all across the world. and at first look at the photo ,she looks like she is of Indian decsent...? could be a very interesing catch for us.?
poorinvester
i have investments here and also with Avacta who regularly send out an rns or updates to it's investers. so disagree on that point, but they put out a statement earlier in the ear that it was an exciting year for the company , and this has been proven over the last 3 months , still more to come i think , it has taken that long for the contracts to come through and get signed off , and to your second point ,i agree we need to wait and make progress slowly and RMS will turn up. LONG TERM .IMO.?
Just received an email off VIRION MASK .to reorder masks at 20% off.
Today's Top Stories
St Brides Partners Weekly Brief, Saturday 13th March 2021
St Brides Partners Weekly Brief, Saturday 13th March 2021
We started this week with the celebration of International Women’s Day, a day dedicated to paving the way to a gender equal world and to highlight women’s achievements.
Read more
Pharm2Farm: Revolutionary Anti-viral face mask kills 99.9% of Covid-19 virus on contact
Pharm2Farm: Revolutionary Anti-viral face mask kills 99.9% of Covid-19 virus on contact
New Pro-Larva mask incorporates unique British copper nanoparticle technology to create a virucidal barrier effective against Covid-19 and other viruses, including influenza
Read more
Mumbo Jumbo
Have you read the oxford study where they have have wittled down companies from about 50 or so in different stages they are completing stage 4 now. but they are only mentioning Innova but there are other companies left in the trials either 3 or 4,from my understanding these will be the only applicants to bid for the 8 billion lft,testing. i may be wrong.???
& Company News
Update on Pharm2Farm’s COVID-19 mask project
05 March 2021, 14:41
Source - LSE Regulatory
RNS Number : 9824C
Braveheart Investment Group plc
23 October 2020
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
23 October 2020
Braveheart Investment Group plc
("Braveheart" or the "Group")
Update on Pharm2Farm's COVID-19 mask project
Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited ("P2F") anti-viral surgical mask project.
P2F has developed a coating for textiles which incorporates its proprietary nanoparticles to give textiles long lasting virucidal properties. The first application of this technology has been to coat a fabric layer in surgical masks and produce a certified antiviral (including COVID-19 and Influenza) mask for use by both healthcare professionals and the public.
P2F has now overcome the delay in testing, reported on 8 October 2020, by conducting live virus tests at two independent UK laboratories. These tests confirmed that the coated face mask textile displayed high virucidal activity, meeting the requirements for ISO 18184 certification with more than a 90% kill rate for up to 7 hours, while being benign to healthy mammalian cells (ISO 18184 is the international anti-viral textile standard that measures virucidal antimicrobial activity on textiles and other porous materials).
The manufacturing process for this new formulation, along with its antiviral, antibacterial and antiparasitic properties has now been submitted as a patent application by P2F to protect its intellectual property.
As previously announced on 18 September 2020, P2F has purchased an automated mask production line, which is on track to be delivered in November 2020 and to be commissioned by the end of December 2020. The production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month.
Following this positive test result, P2F plans to produce anti-COVID-19 surgical face masks certified to ISO 18184 for sale by the end of this year.
Further to the announcement of 19 October 2020, Braveheart notes that the conditional sale of its 51.72% holding in Pharm 2 Farm Limited to Remote Monitored Systems plc ("RMS") is expected to complete on 5 November 2020 (the "Sale"). The Sale is subject to, amongst other things, the passing of the resolutions, including the resolution seeking approval of the whitewash of Braveheart's Rule 9 obligations by the independent shareholders of RMS, at the General Meeting of RMS being held on 4 November 2020.
Following the completion of the Sale, Braveheart will hold 509,992,40